Budesonide Following Endoscopic Dilatation of Esophageal Strictures in Children.
Single-blinded, Randomized Controlled Trial of Budesonide Following Endoscopic Dilatation of Esophageal Strictures in Children.
Endoscopic balloon dilatation (EBD) is a common therapeutic procedure performed for esophageal strictures. While the etiologies of esophageal strictures are numerous - including congenital strictures, caustic injuries and eosinophilic esophagitis (EoE) -anastomotic strictures following esophageal atresia and trachea-esophageal fistula repairs is reported as the most frequent cause in children.
Stricture dilatation is usually performed under direct endoscopic vision, with graduated balloon dilatation, utilizing increasing balloon diameters deployed until reaching a pre-determined, age-based, dilatation target. Balloon dilatation is repeated every 2-4 weeks until the target is reached. Success is defined as prolonged restoration of effective swallow with no dysphagia or dietary restrictions. Dilatation is repeated if clinical resolution is not obtained, or if symptoms return after initial resolution.
In children, a stricture is considered refractory when the age-appropriate esophageal lumen is not achieved with five dilatations within 5 months, or if despite ≥7 dilatations overall an age-appropriate esophageal lumen was not maintained.
Several interventions have been studied to improve the efficacy of balloon dilatation, including injecting corticosteroids at the dilatation site, topical Mitomycin C following dilatation, or pre-dilatation endoscopic incisions of the anastomotic scar tissue. All these interventions are performed endoscopically at the time of the dilatation, require advanced endoscopic skills and may potentially have associated additional risk.
In this study the investigators aim to test the efficacy and safety of topical budesonide gel following EBD for anastomotic esophageal strictures in a single-blinded, randomized controlled study of children.
研究概览
详细说明
This single-blinded randomized controlled trial aims to prospectively evaluate the efficacy of swallowed budesonide gel following EBD of esophageal strictures. Due to the variable nature of congenital strictures and the more disparate features of caustic and EoE strictures, the study is limited to simple strictures at the site of anastomoses.
Patients will be assessed as per the ESPGHAN and NASPGHAN guidelines for the evaluation and treatment of children with esophageal atresia-trachoesophageal fistula, with gastroscopy performed either at one-year of age or earlier in symptomatic patients with dysphagia.
Patients in whom an anastomotic esophageal stricture is identified, dilatations will be performed as per physician discretion regarding diameter and timing of dilatations, guided predominantly by the aforementioned treatment guidelines. Patients will be randomly assigned to either budesonide gel (1mg/8mL) 250mcg orally twice daily for 12 weeks from the first dilatation, or to standard of care with no oral budesonide. Treating physician will be blinded to patient treatment Esophageal stricture characteristics will be recorded at each endoscopy with pre-dilation diameter (estimated based on relative size to pre-measured biopsy forceps placed in proximity to the stricture) and maximal dilatation diameter at each session.
Patients will be assessed clinically routinely at 1, 2, 3, 4 and 6 months following initial dilatation, and at 6 months following the last dilatation in the series, during which dysphagia symptom score and patient weight will be assessed.
Success is defined as restoration of effective swallow with no dysphagia or age-appropriate dietary restrictions for 3 months. Outcome measures will include number of EBD procedures until success is achieved, as well as the rate of restenosis (defined clinically as a dysphagia score of ≥1) after success is achieved 6 months following the last EBD procedure.
The primary aim of the study is to assess the number of dilatations required to achieve clinical success between the treatment and placebo group. Secondary aims include rate of refractory strictures, restenosis rate, dysphagia score, patient weight and safety (including cortisol suppression, oral or esophageal fungal infection, and anthropomorphics).
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名：Oren Ledder, Dr
- 电话号码：+972-2-6666743
- 邮箱：orenl@szmc.org.il
学习地点
-
-
-
Jerusalem、以色列、91031
- Shaare Zedek Medical Centre
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
接受健康志愿者
描述
Inclusion Criteria:
- Infants and children < 12 years old with an anastomotic esophageal stricture following repair of congenital esophageal atresia / tracheoesophageal fistula
- Dysphagia score ≥1
- Parental consent
Exclusion Criteria:
- Additional stricture/s besides anastomotic stricture eg. Congenital stricture
- Complicated stricture - including length >2cm, significant angulation or irregularity
- Neurological impairment or other cause of expected limitation to oral intake
- Previous anastomotic dilatations
- Complicated surgical course including need for re-operation, re-fistularization or surgical anastomotic leak
- Suspected or verified thoracic vascular anomaly affecting esophageal patency or function
- Verified co-diagnosis of eosinophilic esophagitis
- Any contraindication to EBD according to treating physician's planned treatment course
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Budesonide arm
Patients will take budesonide gel (1mg/8mL) 250mcg orally twice daily for 12 weeks from the first dilatation.
|
Patients will receive budesonide gel (1mg/8mL) 250mcg orally twice daily for 12 weeks from the first dilatation.
|
|
无干预：Control arm
Patients will not receive any treatment following their dilations.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The number of EBD procedures required to achieve clinical success.
大体时间：From the first dilation up to 6 months after the initial dilation.
|
The number of endoscopic balloon dilatation (EBD) procedures required to achieve clinical success (defined as effective swallowing without dysphagia or dietary restriction for 3 months) will be compared between the Budesonide and control groups.
|
From the first dilation up to 6 months after the initial dilation.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Restenosis rate 6 months after last EBD performed
大体时间：Up to 6 months after the last dilation.
|
The rate of restenosis, defined clinically as a dysphagia score ≥1, will be compared between the Budesonide and control groups.
Restenosis will be assessed following confirmation of clinical success.
|
Up to 6 months after the last dilation.
|
|
Rate of refractory strictures
大体时间：Up to 5 months from the initial dilatation, or until the 7th dilatation, whichever occurs first.
|
The rate of refractory strictures will be compared between the Budesonide and control groups.
A stricture is considered refractory when the age-appropriate esophageal lumen is not achieved after five dilatations within 5 months, or after ≥7 dilatations in total.
|
Up to 5 months from the initial dilatation, or until the 7th dilatation, whichever occurs first.
|
|
Patient Weight
大体时间：Up to 6 months after the last dilation.
|
Weight gain trajectories will be compared between the Budesonide arm and the control arm to evaluate whether improved stricture resolution and swallowing function contribute to improved growth outcomes.
|
Up to 6 months after the last dilation.
|
|
Dysphagia score
大体时间：From baseline until 6 months following the last dilation.
|
Dysphagia scores (modified dysphagia score and visual analogue scale) will be recorded at all scheduled follow-up visits to assess changes in swallowing function over time.
Scores will be compared between the Budesonide and control groups to evaluate whether the intervention results in reduced severity of dysphagia.
The modified dysphagia score, based on the Szegedi et al. scale, ranges from 0 (no swallowing problems) to 6 (aphagia), with increasing scores reflecting greater severity of swallowing impairment, from food avoidance or occasional difficulty to difficulty with semisolids, liquids, or complete inability to swallow.
|
From baseline until 6 months following the last dilation.
|
|
Pre-dilatation stricture diameter at each procedure
大体时间：From baseline until final dilation, on average 6 months following the first.
|
The esophageal stricture diameter immediately prior to balloon dilation will be recorded at each EBD procedure.
Serial measurements will be analyzed to compare stricture remodeling between the Budesonide and control arms, assessing whether the intervention is associated with greater pre-dilatation lumen size over time or reduced re-narrowing between procedures.
|
From baseline until final dilation, on average 6 months following the first.
|
|
Procedure complication rate
大体时间：From the first dilation through 6 months after the final dilation.
|
The rate of procedure and treatment related complications, including iatrogenic esophageal perforation, evidence of cortisol suppression, and oral or esophageal candidiasis, will be assessed to evaluate the safety of Budesonide compared with standard care.
Complications will be identified during each EBD procedure and at all clinical follow-up visits.
|
From the first dilation through 6 months after the final dilation.
|
合作者和调查者
调查人员
- 首席研究员：Oren Leder, MD、Shaare Zedek Medical Center
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.